Human endotoxemia as a model of systemic inflammation

K.S. Krabbe; R. Krogh-Madsen; S. Taudorf; B.K. Pedersen; K. Moller; Anne Sofie Andreasen

Human endotoxemia as a model of systemic inflammation

K.S. Krabbe, R. Krogh-Madsen, S. Taudorf, B.K. Pedersen, K. Moller, Anne Sofie Andreasen

184 Citationer (Scopus)

Abstract

Systemic inflammation is a pathogenetic component in a vast number of acute and chronic diseases such as sepsis, trauma, type 2 diabetes, atherosclerosis, and Alzheimer's disease, all of which are associated with a substantial morbidity and mortality. However, the molecular mechanisms and physiological significance of the systemic inflammatory response are still not fully understood. The human endotoxin model, an in vivo model of systemic inflammation in which lipopolysaccharide is injected or infused intravenously in healthy volunteers, may be helpful in unravelling these issues. The present review addresses the basic changes that occur in this model. The activation of inflammatory cascades as well as organ-specific haemodynamic and functional changes after lipopolysaccharide are described, and the limitations of human-experimental models for the study of clinical disease are discussed. Finally, we outline the ethical considerations that apply to the use of human endotoxin model
Udgivelsesdato: 2008

Originalsprog	Engelsk
Tidsskrift	Current Medicinal Chemistry
Vol/bind	15
Udgave nummer	17
Sider (fra-til)	1697-1705
Antal sider	8
ISSN	0929-8673
Status	Udgivet - 2008

Citationsformater

@article{c8bb2c30979311de8bc9000ea68e967b,

title = "Human endotoxemia as a model of systemic inflammation",

abstract = "Systemic inflammation is a pathogenetic component in a vast number of acute and chronic diseases such as sepsis, trauma, type 2 diabetes, atherosclerosis, and Alzheimer's disease, all of which are associated with a substantial morbidity and mortality. However, the molecular mechanisms and physiological significance of the systemic inflammatory response are still not fully understood. The human endotoxin model, an in vivo model of systemic inflammation in which lipopolysaccharide is injected or infused intravenously in healthy volunteers, may be helpful in unravelling these issues. The present review addresses the basic changes that occur in this model. The activation of inflammatory cascades as well as organ-specific haemodynamic and functional changes after lipopolysaccharide are described, and the limitations of human-experimental models for the study of clinical disease are discussed. Finally, we outline the ethical considerations that apply to the use of human endotoxin model Udgivelsesdato: 2008",

author = "K.S. Krabbe and R. Krogh-Madsen and S. Taudorf and B.K. Pedersen and K. Moller and Andreasen, {Anne Sofie}",

year = "2008",

language = "English",

volume = "15",

pages = "1697--1705",

journal = "Current Medicinal Chemistry",

issn = "0929-8673",

publisher = "Bentham Science Publishers",

number = "17",

}

TY - JOUR

T1 - Human endotoxemia as a model of systemic inflammation

AU - Krabbe, K.S.

AU - Krogh-Madsen, R.

AU - Taudorf, S.

AU - Pedersen, B.K.

AU - Moller, K.

AU - Andreasen, Anne Sofie

PY - 2008

Y1 - 2008

N2 - Systemic inflammation is a pathogenetic component in a vast number of acute and chronic diseases such as sepsis, trauma, type 2 diabetes, atherosclerosis, and Alzheimer's disease, all of which are associated with a substantial morbidity and mortality. However, the molecular mechanisms and physiological significance of the systemic inflammatory response are still not fully understood. The human endotoxin model, an in vivo model of systemic inflammation in which lipopolysaccharide is injected or infused intravenously in healthy volunteers, may be helpful in unravelling these issues. The present review addresses the basic changes that occur in this model. The activation of inflammatory cascades as well as organ-specific haemodynamic and functional changes after lipopolysaccharide are described, and the limitations of human-experimental models for the study of clinical disease are discussed. Finally, we outline the ethical considerations that apply to the use of human endotoxin model Udgivelsesdato: 2008

AB - Systemic inflammation is a pathogenetic component in a vast number of acute and chronic diseases such as sepsis, trauma, type 2 diabetes, atherosclerosis, and Alzheimer's disease, all of which are associated with a substantial morbidity and mortality. However, the molecular mechanisms and physiological significance of the systemic inflammatory response are still not fully understood. The human endotoxin model, an in vivo model of systemic inflammation in which lipopolysaccharide is injected or infused intravenously in healthy volunteers, may be helpful in unravelling these issues. The present review addresses the basic changes that occur in this model. The activation of inflammatory cascades as well as organ-specific haemodynamic and functional changes after lipopolysaccharide are described, and the limitations of human-experimental models for the study of clinical disease are discussed. Finally, we outline the ethical considerations that apply to the use of human endotoxin model Udgivelsesdato: 2008

M3 - Journal article

SN - 0929-8673

VL - 15

SP - 1697

EP - 1705

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

IS - 17

ER -